Our experience, your guarantee

Hyaltech was founded as a research & development company in 1981 focused on the development of continuous fermentation processes including production of HA for medical applications. Hyaltech has leveraged its HA biotechnology platform to develope and manufacture high quality  HA medical solutions that offer benefits to patients, meet the needs of healthcare providers and sustain the business of our partners.

Timeline of Events:

Foundation of Fermentech

Fermentech receives CE-mark approval for Ophthalin, an ophthalmic viscosurgical device, OVD,  for cataract surgery.

Fermentech receives CE-mark approval for Ophthalin plus, an OVD for cataract surgery.

Fermentech receives CE-mark approval for Fermathron, a viscosupplement for knee osteoarthritis.

Fermentech merged with Swedish IVF Science company becoming Vitrolife UK

Acquisition of Vitrolife UK by Ioltech SA, becoming Hyaltech Ltd.
Hyaltech receives CE-mark approvl for VISTHESIA-the first and only OVD with ancillary lidocaine. Market launch of VISTHESIA by Ioltech SA.

Acquisition of Ioltech SA/Hyaltech Ltd by Carl Zeiss Meditec AG.
Hyaltech receives CE-mark for rejuvenation medical device with lidocaine-Zetavisc-L
Hyaltech receives CE-mark for Sigmavisc for endoscopic mucosal resection

Hyaltech receives CE-mark for TWINVISC-two OVD\'s-in a double chamber syringe. Market launch of TWINVISC by Ioltech SA/Carl Zeiss Meditec AG

Hyaltech receives CE-mark for viscosupplement, for pain relief in case of ankle sprain and elbow injury

Hyaltech receives CE-mark for a double chamber viscosupplement for pain relief in knee osteoarthritis.

Hyaltech moved to  Starlaw Business Park in Livingston to increase capacity and meet market demands.
Hyaltech receives CE-mark for Fermathron plus, a high molecular viscosuppment for the treatment of knee osteoarthritis.

Hyaltech receives CE-mark for Fermathron S, a single injection viscosupplement for knee osteoarthritis